StreetInsider.com News Articles

Canaccord Starts BridgeBio Pharma (BBIO) at Buy

Wed, 03 Jun 2026 05:59:41 -0400

Canaccord analyst Whitney Ijem initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Buy rating, PT $104.00

For an analyst ratings summary and ratings history on BridgeBio Pharma click here. For more ratings news on BridgeBio Pharma click here.

Shares of BridgeBio Pharma closed at $63.88 yesterday.

Form SCHEDULE 13G BridgeBio Pharma, Inc. Filed by: Farallon Capital Partners, L.P.

Fri, 29 May 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260529/26576117.html

Form SCHEDULE 13G BridgeBio Pharma, Inc. Filed by: Farallon Capital Partners, L.P.

Fri, 29 May 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260529/26576117.html

Form 8-K BridgeBio Pharma, Inc. For: May 27

Wed, 27 May 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260527/26557624.html

Form 8-K BridgeBio Pharma, Inc. For: May 27

Wed, 27 May 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260527/26557624.html

BridgeBio receives FDA priority review for muscular dystrophy drug

Wed, 27 May 2026 07:30:17 -0400

BridgeBio Pharma Inc. (NASDAQ: BBIO) announced the FDA has accepted its new drug application for BBP-418, an oral treatment for limb-girdle muscular dystrophy type 2I/R9, and granted priority review status.

The FDA assigned a target action date of November 27, 2026, under the Prescription Drug User Fee Act. The agency indicated it does not currently plan to hold an advisory committee meeting for the application.

BBP-418 met all primary and secondary endpoints in the Phase 3 FORTIFY trial at a 12-month interim analysis, according to the company's press release. The trial showed treated individuals improving while placebo recipients declined across measured outcomes.

BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9

Wed, 27 May 2026 07:30:00 -0400

- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for treatment options for the LGMD2I/R9 community

- If approved, BBP-418 would be the first and only therapy for individuals living with LGMD2I/R9 and would represent the first approved treatment for any form of LGMD

- BBP-418 demonstrated strong, consistent efficacy across all prespecified subgroups with treated individuals improving on every key endpoint while placebo recipients declined, reflecting both the natural progression of this devastating disease

BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9

Wed, 27 May 2026 07:30:00 -0400

- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for treatment options for the LGMD2I/R9 community

- If approved, BBP-418 would be the first and only therapy for individuals living with LGMD2I/R9 and would represent the first approved treatment for any form of LGMD

- BBP-418 demonstrated strong, consistent efficacy across all prespecified subgroups with treated individuals improving on every key endpoint while placebo recipients declined, reflecting both the natural progression of this devastating disease

Form 4 BridgeBio Pharma, Inc. For: May 21 Filed by: Kumar Neil

Tue, 26 May 2026 16:54:00 -0400
si-local-file:///var/storage/secattach/20260526/26550977.html

Form 4 BridgeBio Pharma, Inc. For: May 21 Filed by: Kumar Neil

Tue, 26 May 2026 16:54:00 -0400
si-local-file:///var/storage/secattach/20260526/26550977.html

Raymond James Downgrades BridgeBio Pharma (BBIO) to Market Perform

Tue, 26 May 2026 03:49:20 -0400

Raymond James analyst Martin Auster downgraded BridgeBio Pharma (NASDAQ: BBIO) from Outperform to Market Perform.
The analyst comments: “Attruby continues to gain share among TTR stabilizers, however, we think increasing payer-driven risks into 2031 Vyndamax LOE may result in shares struggling to sustain meaningful upside even as multiple new drug launches diversify the revenue base. Downgrade rating to Market Perform.
The ATTR-CM market is substantial (BBIO projects ~$20B+ peak global sales), and we expect payers will show increasing interest in controlling long-term drug spend in the segment. While formulary pressures are likely to impact both TTR stabilizers and silencers in coming years,

Raymond James Downgrades BridgeBio Pharma (BBIO) to Market Perform

Tue, 26 May 2026 03:49:20 -0400

Raymond James analyst Martin Auster downgraded BridgeBio Pharma (NASDAQ: BBIO) from Outperform to Market Perform.
The analyst comments: “Attruby continues to gain share among TTR stabilizers, however, we think increasing payer-driven risks into 2031 Vyndamax LOE may result in shares struggling to sustain meaningful upside even as multiple new drug launches diversify the revenue base. Downgrade rating to Market Perform.
The ATTR-CM market is substantial (BBIO projects ~$20B+ peak global sales), and we expect payers will show increasing interest in controlling long-term drug spend in the segment. While formulary pressures are likely to impact both TTR stabilizers and silencers in coming years,

Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil

Thu, 21 May 2026 16:32:00 -0400
si-local-file:///var/storage/secattach/20260521/26535994.html

Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil

Thu, 21 May 2026 16:32:00 -0400
si-local-file:///var/storage/secattach/20260521/26535994.html

Form 4 BridgeBio Pharma, Inc. For: May 16 Filed by: Trimarchi Thomas

Tue, 19 May 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260519/26521702.html

Form 4 BridgeBio Pharma, Inc. For: May 16 Filed by: Trimarchi Thomas

Tue, 19 May 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260519/26521702.html

Form 4 BridgeBio Pharma, Inc. For: May 16 Filed by: Kumar Neil

Tue, 19 May 2026 16:28:00 -0400
si-local-file:///var/storage/secattach/20260519/26521630.html

Form 4 BridgeBio Pharma, Inc. For: May 16 Filed by: Kumar Neil

Tue, 19 May 2026 16:28:00 -0400
si-local-file:///var/storage/secattach/20260519/26521630.html

Form 4 BridgeBio Pharma, Inc. For: May 16 Filed by: Apuli Maricel

Tue, 19 May 2026 16:27:00 -0400
si-local-file:///var/storage/secattach/20260519/26521610.html

Form 4 BridgeBio Pharma, Inc. For: May 16 Filed by: Apuli Maricel

Tue, 19 May 2026 16:27:00 -0400
si-local-file:///var/storage/secattach/20260519/26521610.html

Form 4 BridgeBio Pharma, Inc. For: May 15 Filed by: Scott Randal W.

Tue, 19 May 2026 16:26:00 -0400
si-local-file:///var/storage/secattach/20260519/26521597.html

Form 4 BridgeBio Pharma, Inc. For: May 15 Filed by: Scott Randal W.

Tue, 19 May 2026 16:26:00 -0400
si-local-file:///var/storage/secattach/20260519/26521597.html

Form 144 BridgeBio Pharma, Inc. Filed by: Trimarchi Thomas

Mon, 18 May 2026 16:24:00 -0400
si-local-file:///var/storage/secattach/20260518/26514226.html

Form 144 BridgeBio Pharma, Inc. Filed by: Trimarchi Thomas

Mon, 18 May 2026 16:24:00 -0400
si-local-file:///var/storage/secattach/20260518/26514226.html

Citi Starts BridgeBio Pharma (BBIO) at Neutral

Mon, 18 May 2026 16:15:46 -0400

Citi analyst Eric Joseph initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Neutral rating and a price target of $82.00.
For an analyst ratings summary and ratings history on BridgeBio Pharma click here. For more ratings news on BridgeBio Pharma click here.
Shares of BridgeBio Pharma closed at $66.13 yesterday.